Literature DB >> 22726657

Inflammation in viral myocarditis: friend or foe?

Maarten F Corsten1, Blanche Schroen, Stephane Heymans.   

Abstract

Viral myocarditis is an important cause of heart failure for which no specific treatments are available. Direct viral injury to cardiac cells provokes an inflammatory response that significantly contributes to cardiac damage and ensuing morbidity. Despite the central pathogenic role of autoimmune injury, broad inhibition of the inflammatory response does not result in patient benefit. Many preclinical studies collectively emphasize that modulating distinct inflammatory signaling pathways may yield effective viral clearance while preserving cardiac structure. This review aims to provide an overview of the sometimes contrasting observations from experimental viral myocarditis models and to translate the lessons learned into opportunities for future investigations and therapies.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22726657     DOI: 10.1016/j.molmed.2012.05.005

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  47 in total

1.  NF-κB activation is cell type-specific in the heart.

Authors:  Efraín E Rivera-Serrano; Barbara Sherry
Journal:  Virology       Date:  2016-12-30       Impact factor: 3.616

2.  Immunological and pathological consequences of coxsackievirus RNA persistence in the heart.

Authors:  Claudia T Flynn; Taishi Kimura; Kwesi Frimpong-Boateng; Stephanie Harkins; J Lindsay Whitton
Journal:  Virology       Date:  2017-12       Impact factor: 3.616

3.  Three immune-mediated disease models induced by Theiler's virus: Multiple sclerosis, seizures and myocarditis.

Authors:  Ikuo Tsunoda; Fumitaka Sato; Seiichi Omura; Mitsugu Fujita; Namie Sakiyama; Ah-Mee Park
Journal:  Clin Exp Neuroimmunol       Date:  2016-10-25

Review 4.  Troponin I-interacting protein kinase: a novel cardiac-specific kinase, emerging as a molecular target for the treatment of cardiac disease.

Authors:  Hind Lal; Firdos Ahmad; Shan Parikh; Thomas Force
Journal:  Circ J       Date:  2014-06-05       Impact factor: 2.993

5.  Correlations of the changes in bioptic findings with echocardiographic, clinical and laboratory parameters in patients with inflammatory cardiomyopathy.

Authors:  Jan Krejci; Petr Hude; Hana Poloczkova; Vita Zampachova; Radka Stepanova; Tomas Freiberger; Eva Nemcova; Lenka Spinarova
Journal:  Heart Vessels       Date:  2014-12-25       Impact factor: 2.037

6.  Circulating MicroRNAs: a Potential Biomarker for Cardiac Damage, Inflammatory Response, and Left Ventricular Function Recovery in Pediatric Viral Myocarditis.

Authors:  Lior Goldberg; Tal Tirosh-Wagner; Amir Vardi; Haya Abbas; Nir Pillar; Noam Shomron; Yael Nevo-Caspi; Gideon Paret
Journal:  J Cardiovasc Transl Res       Date:  2018-06-18       Impact factor: 4.132

7.  Unc93b1 -Dependent Endosomal Toll-Like Receptor Signaling Regulates Inflammation and Mortality during Coxsackievirus B3 Infection.

Authors:  Erin I Lafferty; Sean A Wiltshire; Isabelle Angers; Silvia M Vidal; Salman T Qureshi
Journal:  J Innate Immun       Date:  2015-02-11       Impact factor: 7.349

8.  In vivo ablation of type I interferon receptor from cardiomyocytes delays coxsackieviral clearance and accelerates myocardial disease.

Authors:  Nadine Althof; Stephanie Harkins; Christopher C Kemball; Claudia T Flynn; Mehrdad Alirezaei; J Lindsay Whitton
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

9.  Ulinastatin Protects against CVB3-Induced Acute Viral Myocarditis through Nrf2 Activation.

Authors:  Fangqiang Song; Fanpo Kong; Hongqing Zhang; Yongqin Zhou; Ming Li
Journal:  Inflammation       Date:  2018-06       Impact factor: 4.092

10.  Andrographolide attenuates viral myocarditis through interactions with the IL-10/STAT3 and P13K/AKT/NF-κβ signaling pathways.

Authors:  Yaxin Zhao; Meng Wang; Yang Li; Wanting Dong
Journal:  Exp Ther Med       Date:  2018-06-29       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.